We have investigated the association between methylenetetrahydrofolate reductase A1298C polymorphism and cervical cancer. A comprehensive search was conducted in Wanfang, China HowNet and PubMed databases to retrieve Chinese and English literature from the construction of the database to December 2019. Stata software was utilized to conduct the analysis of the five genetic models, while the odds ratio and 95% confidence interval were employed to assess the correlation. 12 pertinent publications were included with 3839 subjects (1546 patients and 2293 healthy control). There were no significant associations between A1298C and cervical cancer risk under recessive model, dominant model, allele model, co -dominant model. In the sub -analysis by ethnic groups, a significant association between A1298C and cervical cancer risk under recessive model in Asia. It is suggested a potential association between methylenetetrahydrofolate reductase gene polymorphism A1298C and an elevated susceptibility to cervical cancer in the Asian population, specifically under the recessive model.

In this study,the distribution,metabolism and tumor targeting efficiency of Enolase 1(ENO1)monoclonal antibody(mAb)in cervical cancer bearing mice were investigated by near infrared fluorescence imaging.The relationship between ENO1 expression and tumor stage,prognosis and tumor immune invasion was analyzed by cancer genome atlas.Cy7-NHS and FITC were coupled with ENOl mAb to form Cy7-ENO1 mAb and FITC-ENOl mAb,and the localization of ENOl mAb in cervical cancer cell TC-1 was verified by laser confocal microscopy,and the subcutaneous tumor model of cervical cancer was established.Near infrared fluorescence(NIRF)imaging was performed at 1,6,24,48,72.and 120 h after caudal intravenous injection of Cy7-ENO1 mAb.After 24 h of imaging,major organs were rapidly dissected for in vitro imaging.Bioinformatics results showed significant differences in the expression of ENOl between normal cervical tissue and cervical cancer tissue while immunohistochemistry(IHC)indicated higher ENOl protein expression in cervical cancer tissues.In addition,the expression of ENOl was significantly correlated with tumor stage and lymph node stage,and the high expression of ENO1 was correlated with multiple glycolytic enzymes.Confocal laser microscopy showed that FITC-ENOl mAb could specifically bind to the surface of TC-1 cell membrane,and no cell internalization was observed.Near infrared fluorescence imaging showed that Cy7-ENO1 mAb was mainly enriched in liver,kidney and tumor tissues,and had high tumor targeting efficiency.NIRF imaging allows real-time and dynamic monitoring of ENOl mAb distribution in cervical cancer bearing mice,whose metabolic organs are mainly liver and kidney,and confirms ENOl mAb's targeting of cervical cancer.

卵巢癌是致命的妇科恶性肿瘤之一,具有早期诊断困难、复发率和死亡率高等特点.尽管大多数患者在积极治疗后达到临床缓解,但超过80％的患者可能会发生耐药复发,且通常伴有淋巴结以及广泛腹腔转移.因此,亟需寻找卵巢癌治疗的新策略以延长患者的生存期及减少复发.近红外荧光免疫治疗(near-infrared photoimmunotherapy,NIR-PIT)是一种新型的分子靶向疗法,其主要结合抗体靶向肿瘤的特异性和光吸收染料暴露于近红外光后引起的毒性诱导高特异性的细胞免疫原性死亡,在肿瘤的早期诊断、治疗和耐药中发挥重要作用.综述NIR-PIT抗肿瘤作用的机制及其在卵巢癌中的研究进展.

脂质体作为一种药物递送的靶向载体，被认为是目前最成熟与最具前景的纳米给药系统,脂质体在药物递送方面得到广泛研究。本文通过查阅和归纳汇总近几年相关文献，综述了脂质体的种类，制备方法及临床应用，旨在为脂质体药物的进一步研究与开发提供参考。

近年来,随着精准医学的发展,出现很多肿瘤诊疗的新方法,而精准医疗的基础是实现分子靶向治疗,分子成像技术的应用使其得到进一步的升华,可对活体动物体内特定的基因、细胞、分子及药物进行非侵入性的连续性体内监测,被广泛应用于肿瘤的诊断、治疗及新药研发筛选等领域.本文主要综述分子放射性核素成像、磁共振成像、超声成像、生物发光成像和近红外荧光成像的成像方式及其在肿瘤诊断、治疗中的作用,为肿瘤诊疗提供一个新思路.